Tag: Phase II Trial
Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial
Phase 2 study continues to show AQST-109 is safe and well tolerated.
Positive Early Results with Fecal Microbiota Therapy for Peanut-Allergic Patients
Encapsulated stool from non-allergic donors alters the immune system and increases tolerance to peanuts.
Revolo Biotherapeutics Announces Open Enrollment for Phase 2 Clinical Trial of...
Revolo Biotherapeutics announced it has activated clinical sites and opened enrollment in a Phase 2 clinical trial of its eosinophilic esophagitis therapy.
COUR Announces First In-Human Dosing in Proof-of-Concept Trial of CNP-201 to...
CNP-201 is a nanoparticle containing peanut protein that aims to eliminate allergic responses.
Alladapt Enrolling Participants for Clinical Study of OIT Therapy to Treat...
The study is still seeking participants 4-55 years of age.
Michigan Medicine Helps Lead First National Study on How Highly Allergic...
First volunteer expected to receive an injection April 7 in Ann Arbor with results anticipated this summer.
Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT
Continuing with a modest dose confers more protection, NIH-funded study finds.
New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and...
UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...
AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate
AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
